CRVO - CervoMed Inc.

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.

52W High

$20.63

52W Low

$1.80

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-6.25

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.64

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

12.50

P/B (<3 favorable)

2.74

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

31.40%

Institutions (25–75% balanced)

23.56%

Shares Outstanding

8,702,700

Float

5,480,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

7,777,000

Gross Profit (TTM)

-14,381,149

EPS (TTM)

-2.63

Profit Margin (>10% good)

-2.91%

Operating Margin (TTM) (higher better)

-3.76%

ROE (TTM) (>15% strong)

-0.54%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.47

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—